Management of Candida species infections in critically ill patients

Lancet Infectious Diseases

Volumn 3, Issue 12, 2003, Pages 772-785

  Eggimann, Philippe ^a   Garbino, Jorge ^a   Pittet, Didier ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; HEAT SHOCK PROTEIN 90 ANTIBODY; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NORFLOXACIN; NYSTATIN; POLYMYXIN; POSACONAZOLE; PROBIOTIC AGENT; PROTEIN ANTIBODY; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; BRONCHOSPASM; CANDIDA; CELL INVASION; CHILL; CRITICAL ILLNESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESISTANCE; FEVER; FUNGEMIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; HYPOKALEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INJECTION PAIN; KIDNEY DISEASE; LIVER DISEASE; MORTALITY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEPTIC SHOCK; SIDE EFFECT; THROMBOPHLEBITIS; TREATMENT INDICATION; VOMITING;

EID: 0345414664     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00831-4     Document Type: Review

References (177)

1. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526-30.
2. Wey SB, Motomi M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-45.
3. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
4. Debusk CH, Daoud R, Thirumoorthi MC, Wilson FM, Khatib R. Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors. Scand J Infect Dis 1994; 26: 697-703.
5. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
6. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis by different Candida species. Clin Infect Dis 1997; 24: 1122-28.
7. Girmenia C, Martino P. Fluconazole and the changing epidemiology of candidemia. Clin Infect Dis 1998; 27: 232-34.
8. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-40.
9. Wingard JR, Merz WG, Rindali MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-77.
10. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-85.
11. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
12. Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care center. Eur J Clin Microbiol Infect Dis 2000; 19: 602-07.
13. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-85.
14. British Society for Antimicrobial Chemotherapy. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994; 20: 522-28.
15. Edwards JEJ, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
16. Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Car Med 1998; 24: 206-16.
17. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
18. Buchner T, Fegeler W, Bernhardt H, et al. Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis 2002; 21: 337-52.
19. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-40.
20. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 of 24 hours: randomised controlled trial. BMJ 2001; 322: 579-82.
21. Patel R. Symposium on antimicrobial agents: part III-amphotericin B preparations and flucytosine. Mayo Clin Proc 1998; 73: 1205-25.
22. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21: 1145-53.
23. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96.
24. Caillot D, Chavanet P, Casasnovas O, et al. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis 1992; 11: 722-25.
25. Chavanet P, Charlier N, Brenet A, et al. Emulsion of amphotericin B in Intralipid 20%: in vitro efficacy. Pathol Biol 1992; 40: 507-12.
26. Arikan S, Rex JH. Nystatin LF (Aronex/Abbott). Curr Opin Investig Drugs 2001; 2: 488-95.
27. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331-40.
28. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002; 34: 600-02.
29. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-35.
30. Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61: 1121-29.
31. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-79.
32. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979; 301: 126-31.
33. Bennet JE. Flucytosine. Ann Intern Med 1977; 86: 319-21.
34. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15: 1003-18.
35. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997; 24: 235-47.
36. Dick JD, Rosengard BR, Merz WG, Stuart RK, Hutchins GM, Saral R. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med 1985; 102: 67-68.
37. Merz WG. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 1984; 20: 1194-95.
38. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-12.
39. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-71.
40. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
41. Gotzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2002; 4: CD002033.
42. Krupova Y, Mistrik M, Bojtarova E, Sejnova D, Ilavska I, Krcmery VJ. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Support Care Cancer 2001; 9: 209-10.
43. Denning DW, Warn P. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob Agents Chemother 1999; 43: 2592-99.
44. Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M, et al. In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol 2002; 40: 1406-412.
45. Utz JP. Flucytosine. N Engl J Med 1972; 286: 777-78.
46. Barchiesi F, Caggiano G, Maracci M, Arzeni D, Scalise G, Montagna MT. Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. J Antimicrob Chemother 2003; 51: 431-33.
47. Vermes A, van Der S, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000; 46: 86-94.
48. Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24: 426-32.
49. Silling G, Fegeler W, Roos N, Essink M, Buchner T. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999; 42 (suppl 2): 101-04.
50. Utz JP. Chemotherapy for the systemic mycoses: the prelude to ketoconazole. Rev Infect Dis 1980; 2: 625-32.
51. Walsh TJ, Rubin M, Hathorn J, et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients: a prospective, randomized study. Arch Intern Med 1991; 151: 765-70.
52. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-72.
53. Herbrecht R, Letscher-Bru V, Fohrer C, et al. Acremonium strictum pulmonary infection in a leukemic patient successfuly treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis 2002; 21: 814-17.
54. Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42: 741-45.
55. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 2001; 61 (suppl 1): 39-47.
56. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001; 26: 159-69.
57. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 381: 1325-30.
58. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997; 16: 337-45.
59. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72.
60. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155: 2429-35.
61. Duswald KH, Penk A, Pittrow L. High-dose therapy with fluconazole > or = 800 mg day-1. Mycoses 1997; 40: 267-277.
62. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993; 26: 133-46.
63. Voss A, de Pauw BE. High-dose fluconazole therapy in patients with severe fungal infections. Eur J Clin Microbiol Infect Dis 1999; 18: 165-74.
64. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91: 137-41.
65. Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 1997; 24: 375-80.
66. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-37.
67. Pfaller MA, Diekema DJ, Messer SA, Boyken L Hollis RJ, Jones RN. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83.
68. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41: 2492-96.
69. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
70. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998; 42: 313-18.
71. Arikan S, Rex JH. Ravuconazole Eisai/Bristol-Myers Squibb. Curr Opin Investig Drugs 2002; 3: 555-61.
72. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34: 1648-50.
73. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 1108-11.
74. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-55.
75. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-29.
76. Stone JA, Holland SD, Wickersham PJ, et al. Single-and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-45.
77. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
78. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001; 14: 685-91.
79. Arevalo MP, Carrillo-Munoz AJ, Salgado J, et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003; 51: 163-66.
80. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002; 43: 13-17.
81. Fromtling RA. Micafungin sodium (fk-463). Drugs Today 2002; 38: 245-57.
82. Laverdiere M, Hoban D, Restieri C, Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002; 50: 119-23.
83. Polak A. The past, present and future of antimycotic combination therapy. Mycoses 1999; 42: 355-70.
84. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-28.
85. Fichtenbaum CJ, German M, Dunagan WC, et al. A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clin Infect Dis 1999; 29: 1551-56.
86. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-99.
87. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002; 45: 141-45.
88. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-45.
89. Rao NA, Hidayat AA. Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am J Ophthalmol 2001; 132: 244-51.
90. Hauser M, Hess J, Belohradsky BH. Treatment of Candida albicans endocarditis: case report and a review. Infection 2003; 31: 125-27.
91. Miller DJ, Mejicano GC. Vertebral osteomyelitis due to Candida species: case report and literature review. Clin Infect Dis 2001; 33: 523-30.
92. Garbino J, Lew PD, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in SDD-treated patients. Intensive Care Med 2002; 28: 1708-17.
93. Rose HD. Venous catheter-associated candidemia. Am J Med Sci 1978; 275: 265-69.
94. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002; 34: 591-99.
95. Nucci M, Silveira MI, Spector N, et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998; 27: 107-11.
96. Nucci M, Colombo AL, Silveira F, et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 2002; 19: 846-50.
97. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995; 21: 994-96.
98. Dato VM, Dajani AS. Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 1990; 9: 309-14.
99. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20: 571-75.
100. Karlowicz MG, Hashimoto LN, Kelly REJ, Buescher ES. Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics 2000; 106: 1-5.
101. Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14: 875-83.
102. Girmenia C, Martino P, De Bernardis F, et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23: 506-14.
103. Tortorano A, Biraghi E, Astolfi A, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002; 51: 297-304.
104. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 2000; 355: 1864-68.
105. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery 1980; 88: 524-30.
106. Solomkin JS, Flohr AB, Simmons RL. Indications for therapy for fungemia in postoperative patients. Arch Surg 1982; 117: 1272-75.
107. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of candida isolated from peritoneum in surgical patients. Lancet 1989; 2: 1437-40.
108. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-58.
109. Sawyer RG, Rosenlof LK, Adams RB, May AK, Spengler MD, Pruett TL. Peritonitis into the 1990s: changing pathogens and changing strategies in the critically ill. Am Surg 1992; 58: 82-87.
110. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
111. Sandven P, Qvist H, Skovlund E, Giercksky KE. Significance of candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30: 541-47.
112. Rantala A, Niinikoski J, Lehtonen OP. Early candida isolations in febrile patients after abdominal surgery. Scand J Infect Dis 1993; 25: 479-85.
113. Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med 2000; 160: 678-82.
114. Paradisi F, Corti G, Mangani V. Urosepsis in the critical care unit. Crit Care Clin 1998; 14: 165-80.
115. National Nosocomial Infection surveillance (NNIS) System report. Data summary from January 1990-May 1999. Am J Infect Control 1999; 27: 520-32.
116. Fisher J, Mayhall G, Duma R, Shadomy S, Shadomy J, Watlington C. Fungus balls of the urinary tract. South Med J 1979; 72: 1281-87.
117. Nassoura Z, Ivatury RR, Simon RJ, Jabbour N, Stahl WM. Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy. J Trauma 1993; 35: 290-94.
118. Fisher JF, Newman CL, Sobel JD. Yeast in the urine: solutions for a budding problem. Clin Infect Dis 1995; 20: 183-89.
119. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samore MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis 1999; 29: 926-28.
120. Neumann PR, Rakower SR. The risk of positive cultures for Candida in the critically ill patient. Crit Care Med 1978; 6: 73-76.
121. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000; 30: 14-18.
122. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000; 30: 19-24.
123. Sobel JD. Management of asymptomatic candiduria. Int J Antimicrob Agents 1999; 11: 285-88.
124. Saint S, Elmore JG, Sullivan SD, Emerson SS, Koepsell TD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med 1998; 105: 236-41.
125. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. Arch Intern Med 2000; 160: 2670-75.
126. Bologna RA, Tu LM, Polansky M, Fraimow HD, Gordon DA, Whitmore KE. Hydrogel/silver ion-coated urinary catheter reduces nosocomial urinary tract infection rates in intensive care unit patients: a multicenter study. Urology 1999; 54: 982-87.
127. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
128. Chastre J, Fagon JY, Trouillet JL. Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Clin Infect Dis 1995; 21 (suppl 3): S226-37
129. Bauer TT, Torres A. Candida pneumonia. Clin Intensive Care 1999; 10: 33-40.
130. el-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients: an immediate postmortem histologic study. Am J Respir Crit Care Med 1997; 156: 583-90.
131. Rello J, Esandi ME, Diaz E, Mariscal D, Gallego M, Valles J. The role of Candida spp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998; 114: 146-49.
132. Haron E, Vartivarian S, Analssie E, Dekmezian R, Bodey GP. Primary Candida pneumonia: experience at a large cancer center and review of the literature. Medicine 1993; 72: 137-42.
133. Pittet D. Candidémie et candidoses généralisé es. In: Encydopédie Médico-Chirurgicale, Anesthé sie-Réanimation 36-983-D-10. Paris: Elsevier SAS, 2000.
134. Menezes AV, Sigesmund DA, Demajo WA, Devenyi RG. Mortality of hospitalized patients with Candida endophthalmitis. Arch Intern Med 1994; 154: 2093-97.
135. Edwards JEJ, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine 1974; 55: 47-75.
136. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine 2003; 82: 187-202.
137. Henderson DK, Edwards JEJ, Montgomerie JZ. Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J Infect Dis 1981; 143: 655-61.
138. Parke DW, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology 1982; 89: 789-96.
139. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 1989; 149: 2226-28.
140. Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidemia: clinical implications derived from a prospective multicenter study. Ophthalmology 1994; 101: 1302-09.
141. Krishna R, Amuh D, Lowder CY, Gordon SM, Adal KA, Hall G. Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye 2000; 14: 30-34.
142. Meyers SM. The incidence of fundus lesions in septicemia. Am J Ophthalmol 1979; 88: 661-67.
143. Neudorfer M, Barnea Y, Geyer O, Siegman-Igra Y. Retinal lesions in septicemia. Am J Ophthalmol 1993; 116: 728-34.
144. Bouza E, Cobo-Soriano R, Rodriguez-Creixems M, Munoz P, Suarez-Leoz M, Cortes C. A prospective search for ocular lesions in hospitalized patients with significant bacteremia. Clin Infect Dis 2000; 30: 306-12.
145. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessement of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
146. Eggimann P, Pittet D. Infection control in the ICU. Chest 2001; 120: 2059-93.
147. Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000; 356: 1307-12.
148. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR Morb Mortal Wkly Rep 2002; 51: 1-45.
149. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2002; 51: 1-29.
150. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998; 338: 232-38.
151. Slotman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122: 147-51.
152. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32: 1191-200.
153. Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997; 314: 1238-44.
154. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
155. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
156. Lumbreras C, Cuervas-Mons V, Jara P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of candida infection following liver transplantation. J Infect Dis 1996; 174: 583-88.
157. Calvo V, Borro JM, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 1999; 115: 1301-04.
158. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 700-05.
159. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection, A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 689-96.
160. Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30: 300-05.
161. Nguyen MH, Peacock JE, Jr., Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23.
162. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246-54.
163. Todd JC, O'Neal VG, Grady KP, Fallon WFJ, Laneve L, Derousie PJ. Reduction of secondary mycotic infections in the trauma intensive care unit with fluconazole. J Trauma 1991; 31: 1722-27.
164. Cerra FB, Maddaus MA, Dunn DL, et al. Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients. Arch Surg 1992; 127: 163-67.
165. Desai MH, Rutan RL, Heggers JP, Herndon DN. Candida infection with and without nystatin prophylaxis: a 11-year experience with patients with burn injury. Arch Surg 1992; 127: 159-62.
166. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-48.
167. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345: 1660-66.
168. Jacobs S, Price ED, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med 2003; 31: 1938-46.
169. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994; 36: 20-25.
170. Ables AZ, Blumer NA, Valainis GT, Godenick MT, Kajdasz DK, Palesch YY. Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000; 9: 169-75.
171. Stuyt RJ, Netea MG, Verschueren I, et al. Role of interleukin-18 in host defense against disseminated Candida albicans infection. Infect Immun 2002; 70: 3284-86.
172. Lilic D. New perspectives on the immunology of chronic mucocutaneous candidiasis. Curr Opin Infect Dis 2002; 15: 143-47.
173. Matthews RC, Burnie JP, Tabaqchali S. Immunoblot analysis of the serological response in systemic candidosis. Lancet 1984; 2: 1415-18.
174. Matthews R, Hodgetts S, Burnie JP. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J Infect Dis 1995; 171: 1668-71.
175. Matthews RC, Burnie JP, Rigg G, Hodgetts S, Nelson JC. Human recombinant antibody to hsp 90 in the treatment of disseminated candidosis. Proceedings of 40th ICAAC, Toronto, Canada, 2000: abstr 063.
176. Brassart D, Woltz A, Golliard M, Neeser JR. In vitro inhibition of adhesion of Candida albicans clinical isolates to human buccal epithelial cells by Fuc alpha 1-2Gal beta-bearing complex carbohydrates. Infect Immun 1991; 59: 1605-13.
177. Wagner RD, Pierson C, Warner T, et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect Immun 1997; 65: 4165-72.